x
Ariana Pharma
[contact-form-7 404 "Not Found"]

Ariana Pharma
  • Contact Us
  • Home
  • About Us
  • Our Business
  • Our Technology
  • Real World Data
  • News & more
    • In The News
    • Case study
    • Publications
      • Publications & Conferences
      • Whitepaper & blog
  • Careers
Logo

Contact Info

  • 58-60 Avenue de la Grande Armée, 75017, Paris, France
  • +33 1 44 37 17 00
  • info@arianapharma.com
Autism

Jan2018

Autism and automatic analysis of hand movements

Kinematics could provide earlier and more specific information than clinicians on developmental problems in general, and those specific to Autism Spectrum Disorder in particular, a published study by Ariana and Necker Children Hospital finds. Developmental Trajectories of Hand Movements in Typical Infants and those at Risk of Developmental Disorders: An Observational Study of Kinematics during […]

Read More
Cancer

Jan2018

Ariana’s KEM® analysis shows positive impact on patient Quality of Life for ValiSeek VAL401 in Phase II trial for NSCLC patients

Further positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients. VAL401 treatment has a measureable improvement on patient Quality of Life, in addition to a significant impact on survival. London, Paris and Boston, 16 January 2018: Ariana Pharma and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, […]

Read More
Cancer

Dec2017

Ariana®’s KEM® data analysis shows positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients

London, Paris and Boston, 12 December 2017: Ariana Pharma and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, today provided a positive update on the clinical progress of VAL401, the anti-cancer compound developed by ValiSeek. Using Ariana’s proprietary KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, the data analysis demonstrates that the VAL401 […]

Read More
Alzheimer's

Nov2017

CTAD 2017 (Boston, USA | 1-4 Nov)

Dr Mohammad Afshar (Ariana CEO) is presenting on the analysis of Phase 2a trial results using Ariana’s KEM® artificial intelligence platform at CTAD 2017 (10th Clinical Trials on Alzheimer’s Disease) in Boston, USA on 4 November. LB18 – Clinical Pharmacokinetics and Pharmacodynamics Characterization of ANAVEX™2-73 for Designing a Phase 2/3 Study in Mild-to-Moderate Alzheimer’s Disease […]

Read More
Alzheimer's

Oct2017

Anavex incorporating Ariana’s KEM® AI platform in Alzheimer’s precision medicine approach

Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease PatientsANAVEX2-73 demonstrates desirable PK/PD properties, describing the relationship between drug concentration and the effect observed.Anavex is incorporating advanced Artificial Intelligence platform for the analysis of Phase 2a results with the aim to increase the chances of success […]

Read More
Cancer

Jun2017

WIN 2017 (Paris | Jun 26-27)

Meet the Ariana team of Dr Mohammad Afshar (CEO) and Dr Mariana Kuras (CTO) at the WIN 2017 Symposium this week. The conference program will elaborate the theme ‘Expediting Global Innovation in Precision Cancer Medicine’ and is the place to be to learn about the latest in cancer research from leading practioners.

Read More
Cancer

May2017

Ariana Pharma finalist in EU eHealth 2017 with Onco KEM

Ariana Pharma were finalists in the Champions Category of the EU eHealth 2017 Competition with its clinical decision support system for oncologists, Onco KEM. Our solution: The right drug to the right patient with Onco KEM®, a novel decision support system helping oncologists to personalize cancer treatments according to the molecular profile of each patient. […]

Read More
Real World Evidence

May2017

API 2017 (Panama | May 16-20)

Two posters highlighting the use of Ariana’s Real World Evidence (RWE) platform for large scale data mining of healthcare records are to be presented at API 2017 (Asociacion Panamericana de Infectologia) – XVIII Congresso Panamericano de Infectologia, Panama, 16-20 May 2017. The studies focus on retrospective analyses of risk factors for dengue mortality in hospitalized […]

Read More
Cancer

May2017

Broadening the reach of Precision Medicine beyond DNA

Initial results of Onco KEM and the WINTHER trial were presented at TAT 2017: 15th International Congress on Targeted Anticancer Therapies, 6-8 Mar 2017, Paris, France. The study demonstrates that the innovative Onco KEM transcriptomic-based decision support system fills a gap left by traditional DNA based targeted therapy, enabling more patients to reach a larger […]

Read More
Cancer

Nov2016

Ariana to present on Combination Therapy in Melanoma with Harvard Medical School (Paris | Nov 29 – Dec 2nd)

Dr Parmentier will present a poster “Combination Therapy in Melanoma: finding biomarkers of synergistic associations using Large Scale Drug Combination Screening and integrated Omics Data Analysis” at the Institut Pasteur International Network Scientific Symposium in Paris on November 30th.   The poster showcases the results of a collaborative study between Ariana and the Massachusetts General […]

Read More

Posts navigation

1 2 3 4 5 6 7

Categories

  • Alzheimer's
  • Autism
  • Autoimmune disease
  • Cancer
  • Fibromyalgia
  • Kidney Transplant
  • Parkinson’s
  • Precision Medicine
  • Publications
  • Real World Evidence
  • Recent Posts
  • Type A Diabetes

Tags

alzheimer's autism cancer Event Fibromyalgia Graft rejection Influenza Kidney Laboratory lung neurological Oncology Professor Jean-Yves BLAY Centre Leon berard Parkinson Parkinson’s precisionmedicine precision medicine publication realworldevidence recent post Recent Posts Research Transplant vaccine

Ariana Pharmaceuticals, The AI DRUG Development Company

  • Paris, FRANCE / Cambridge, MA, USA
  • Call Us: +33 144 37 17 00
  • info@arianapharma.com

Menu

  • About Us
  • Our business
  • Technology
  • In The News
  • Contact Us

Subscribe

Keep in touch and subscribe to our latest news

    Ariana Pharma © 2024 All Rights Reserved